In December of 2024, the FDA granted accelerated approval of the first anti-HER2/HER3 bispecific IgG1 antibody, zenocutuzumab (Bizengri), for the treatment of patients with pancreatic adenocarcinoma and NSCLC harbouring NRG1 gene mutation [128,129]. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.